At 16.9% CAGR, the Europe Cell and Gene Therapy Manufacturing Services Market is Projected to be worth US$ 6,563.85 million by 2030, says Business Market Insights

According to Business Market Insights research, the Europe cell and gene therapy manufacturing services market was valued at US$ 1,879.77 million in 2022 and is expected to reach US$ 6,563.85 million by 2030, registering a CAGR of 16.9% from 2022 to 2030. Automation of cell and gene therapy manufacturing services and strategic initiatives by companies are among the critical factors attributed to the Europe cell and gene therapy manufacturing services market expansion.               

Incorporating automation in cell and gene therapy manufacturing would lead to a reduced risk of contamination, improved consistency, and decreased cost of production. Lonza Cocoon and the CliniMACS Prodigy system from Miltenyi are a few of the devices available in the market to enable automation. These products have been designed to enable the automation of most sequential unit operations for a CAR-T process within a single system. The rising demand for cell and gene therapies has shifted the production of cell and gene therapy products from a small-volume process to a large-volume process worldwide. In addition to the increasing research activities, the evolution of cell and gene therapy from an academic and clinical setting to mass production and commercialization has propelled the demand for automation in commercial manufacturing. In July 2020, Thermo Fisher Scientific Inc. and Lyell Immunopharma partnered to develop and manufacture processes to design effective cell therapies for cancer patients. Under this partnership, the companies aim to improve the capability of T-cells and support the development of an integrated current good manufacturing practice (cGMP) compliant platform (system and software), along with reagents, consumables, and instruments. Further, government agencies are adopting automation in the manufacturing of cell therapies to increase the national production capabilities of the country. For instance, as of March 2023, the UK Stem Cell Bank of the Medicines and Healthcare Products Regulatory Agency (MHRA) was testing automated robotic technology for developing stem cell technology for the manufacturing of stem cell-based therapies. Thus, automation is emerging as a new trend in the cell and gene therapy manufacturing services market.  

On the contrary, high cost of cell and gene therapy manufacturing hurdles the growth of Europe cell and gene therapy manufacturing services market.

Based on type, the Europe cell and gene therapy manufacturing services market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 70.1% share of Europe cell and gene therapy manufacturing services market in 2022, amassing US$ 1,317.27 million. It is projected to garner US$ 4,654.44 million by 2030 to expand at 17.1% CAGR during 2022–2030. The cell therapy segment is further segmented into autologous and allogenic. The gene therapy segment is further segmented into viral and non-viral vector.

Based on indication, the Europe cell and gene therapy manufacturing services market is segmented into cancer, orthopedics, and others. The cancer segment held 56.0% share of Europe cell and gene therapy manufacturing services market in 2022, amassing US$ 1,051.80 million. It is projected to garner US$ 3,917.36 million by 2030 to expand at 17.9% CAGR during 2022–2030.

Based on application, the Europe cell and gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing. The commercial manufacturing segment held 62.4% share of Europe cell and gene therapy manufacturing services market in 2022, amassing US$ 1,173.17 million. It is projected to garner US$ 4,311.11 million by 2030 to expand at 17.7% CAGR during 2022–2030.  

Based on end user, the Europe cell and gene therapy manufacturing services market is bifurcated into pharmaceutical and biotechnology companies and contract research organization (CROs). The pharmaceutical and biotechnology companies segment held 78.1% share of Europe cell and gene therapy manufacturing services market in 2022, amassing US$ 1,468.01 million. It is projected to garner US$ 5,164.35 million by 2030 to expand at 17.0% CAGR during 2022–2030.

Based on country, the Europe cell and gene therapy manufacturing services market is segmented into the UK, France, Germany, Spain, Italy, and the Rest of Europe. Our regional analysis states that the UK captured 30.4% share of Europe cell and gene therapy manufacturing services market in 2022. It was assessed at US$ 570.54 million in 2022 and is likely to hit US$ 2,124.49 million by 2030, exhibiting a CAGR of 17.9% during 2022–2030.  

Key players operating in the Europe cell and gene therapy manufacturing services market are Catalent Inc, Charles River Laboratories International Inc, FUJIFILM Holdings Corp, Lonza Group AG, Merck KgaA, Nikon Corp, Oxford BioMedica Plc, Takara Bio Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com